Introduction: cardiac complication in diabetic patients remained high despite very good control of blood glucose. Our hypothesis is that it was associated with a persistently high endothelin-1 (ET-1) level. To clarify this notion we created a diabetic model by streptozotocin (STZ) injection. Since dysfunction of endothelial cells, which are the main source of ET-1, is believed to have an important role in the pathophysiology of diabetic complications, Bosentan (a non-selective endothelin receptor antagonist) was administered to block ET-1 activity. Aims: to investigate the potential protective effect of Bosentan in diabetic myocardial fibrosis. Materials and methods: 6-week-old male C57BL/6 mice with were divided into three groups (N = 20): control group, DM group (diabetes group) and DM-B group (diabetes with bosentan group). STZ was injected with 200 mg/g, single dose, i.p. (intraperitoneal injection) to make a type 1 diabetic model. Fasting blood glucose (FBG) was measured at weeks 0, 1, and 2 after STZ injection to confirm that the diabetic model existed. Bosentan (100 mg/kg) and placebo were given i.g. (intragastric administration) once a day immediately after STZ injection for 18 weeks. Cardiac fibrosis was evaluated by morphometric analysis. The differences of mRNA expression were compared by real-time PCR. Cardiac systolic function was evaluated by echocardiography. Results: after 18 weeks of diabetic situation, the FBG of DM-B mice was significantly higher than that of control mice and was similar to that of DM mice (DM mice vs. control mice, p < 0.001; DM-B vs. control mice, p < 0.001; DM mice vs. DM-B mice, p > 0.05). Pathological analysis with Masson's Trichrome staining showed significant fibrotic changes in diabetic myocardium, and the fibrosis was ameliorated by bosentan. Furthermore, the area of interstitial fibrosis was markedly lower in DM-B mice. This lower area of interstitial fibrosis is associated with higher expression of cardiac VEGF mRNA (a potent angiogenic factor) in DM-B mice than in DM mice (p < 0.01). The heart of DM-B mice also showed lower expression of fibrotic genes (TGF-ß, CTGF and collagen-1) than in DM mice (p < 0.01). Furthermore, cardiac systolic function (fractional shortening, FS) of DM and DM-B mice decreased after 18 weeks of diabetes (DM vs. control mice, p < 0.001). However, the impairment of cardiac function (FS) was significantly ameliorated, even nearly normalized, by bosentan (DM-B vs. control mice, p > 0.05). Conclusions: these findings indicate the potential usefulness of a ET receptor antagonist bosentan in the amelioration of diabetic cardiac complications (myocardial fibrosis and cardiac dysfunction) without affecting blood glucose. This may provide a promising therapeutical strategy for diabetic cardiac fibrosis.
are directly related to a loss of function in the heart. 6 ECM comprises an insoluble network of collagens, elastins, structural glycoproteins, proteoglycans-hyaluronans and integrins, which not only provide mechanical support for the cells, but also mediate complex interactions between the cells or between cells and the ECM of vascular tissues. 5, 7 Both type I and type III collagen are present in normal and diseased myocardial tissue. Type I collagen is predominant in the myocardium. Responsible for the increased left ventricle (LV) mass, diffuse myocardial fibrosis has a distribution in both interstitium and perivascular sites. Extensive myocyte necrosis and replacement of contractile fibers by connective tissue are likely to account for depressed cardiac performance, at least in advanced stages of diabetic cardiomyopathy. It appears that hypertrophy of myocardial cells and myocardial interstitial fibrosis may be present even in mild hyperglycemia in diabetes. 5, 8 Hyperglycemia is responsible for the presence of high levels of non-enzymatically produced advanced glycation endproducts (AGEs) in diabetic patients. AGEs are able to stimulate directly the production of ECM. 9 Growth factors such as transforming growth factor β (TGF-β), connective tissue growth factor (CTGF), insulin-like growth factor I (IGF-I), fibroblast growth factor (FGF), and epidermal growth factor (EGF) play an important role in the pathogenesis of diabetic complications. Among them, TGF-be present even in mild hyperglycemia in fibrosis has a distribution in bothstages. [10] [11] [12] Vascular endothelial growth factor (VEGF), which is a major mediator of neovascularization in physiologic and pathophysiologic conditions, has crucial effects in blood vessel formation. 2 Endothelin-1 (ET-1) is a potent vasoconstrictor peptide which can also exert profibrotic effects. Up-regulated by glucose, ET-1 linked with matrix accumulation in cardiomyocyte hypertrophy. 13 The present study was designed to investigate the changes of VEGF (a potent angiogenic factor) and fibrotic genes (TGF-ß, CTGF and collagen-1), the cardiac pathology and the potential protective effect of bosentan (nonselective endothelin receptor antagonist) in diabetic cardiac complications, especially myocardial fibrosis. In order to assess accurately the morphological changes in the target organs and the extent to which the fibrotic changes affect their function, we use both invasive studies (tissue pathology, tissue mRNA measurement of fibrotic markers) and non-invasive study (echocardiography).
Materials and methods

Animals
Experimental procedures were performed according to the Guidelines for Animal Experimentation at PLA General Hospital. The protocols were approved by the Ethical Committee. The colony of C57BL/6 mice was kept by Animal Lab in PLA General Hospital. The mice were housed at 24℃, with a normal 12-h light-dark cycle, and were given food and water ad libitum. Male C57BL/6 mice at six weeks old were divided into three groups (N = 20): control group, DM group (diabetes group) and DM-B group (diabetes with bosentan group). After an overnight fast, the mice received a streptozotocin (STZ) injection of 200 mg/kg as a single dose, i.p. (intraperitoneal injection) to create a type 1 diabetic model. STZ was dissolved in a citrate solution (0.1 M citric acid and 0.2 M sodium phosphate, pH 4.5). Control mice received an equivalent volume of citrate buffer alone. Fasting blood glucose (FBG) was measured at weeks 0, 1, and 2 after STZ injection to confirm that mice had developed diabetes. OneTouch Ultra Blood Glucose Meter (LifeScan Inc., USA) was used to test tail vein blood glucose of mice. Bosentan (100 mg/kg, Actelion Ltd, Switzerland) was given to DM-B group mice i.g. (intragastric administration) once a day immediately after STZ injection. Placebo (physiological saline) was given to control group mice and DM group mice. Bosentan and placebo were given for 18 weeks. All mice were fed with the same chow and water until they were sacrificed at 24 weeks old.
Tissue preparation
Mice were anesthetized with 5% Nembutal (62.5 mg/kg BW) i.p. Heart was taken and washed with autoclaved PBS buffer on ice. LV (left ventricle) was isolated and frozen with liquid nitrogen, then put into a 1.5 ml Eppendorf tube and stored at -80℃ until use.
Semiquantitative RT-PCR (Reverse Transcription PCR)
mRNA was extracted from LV as described. 14 mRNA (2 µg) was dissolved in 10 µl of a reaction mixture containing 1 µl of 10 mM dNTP mix; 1 µl of oligo dT enzyme (SuperScript First-Strand Synthesis System for RT-PCR, Invitrogen Co. Ltd, USA). After incubation at 65°C for 5 min, PCR mixture (2 µl of RT buffer, 4 µl of 25 mM MgCl 2 , 2 µl of 0.1 M DTT, 1 µl of RNAse-out Inhibitor, 1 µl of SuperScript-II-RT enzyme) was added into the mRNA mixture. After incubation at 42°C for 50 min, the enzyme was denatured at 70°C for 15 min. RNAse H enzyme was added to the mixture to degradate the surplus mRNA. With these, cDNA was made. The signals were normalized by inner standard GAPDH (glyceraldehydes 3-phosphate dehydrogenase) mRNA. The cDNA PCR amplification was performed with the following profile: one cycle of 95°C for 3 min, 30 cycles of 95°C for 30 s, 66°C for 1 min and 72°C for 30 s; finally, one cycle of 72°C for 10 min (TaKaRa Bio Inc., Japan). The primers were as follows:
VEGF forward: 5′-AGTGGTCCCAGGCTGCAC-3′ VEGF reverse: 5′-TCCATGAACTTCACCACTTCGT-3′ TGF-ß forward: 5′-AACTATTGCTTCAGCTCCAGAGAGA-3′ TGF-ß reverse: 5′-AGTTGGATGGTAGCCCTTG-3′ CTGF forward: 5'′-GGTGAGTCCTTCCAAAGCAGCTGCAAAT-3′ CTGF reverse: 5′-GCAGTTGGCTCGCATCATAGTTGGG-3′ Collagen-1 forward: 5′-ACAGACGAACAACCCAAACT-3′ Collagen-1 reverse: 5′-GGTTTTTGGTCACGTTCAGT-3′ GAPDH forward: 5′-ACCACAGTCCATGCCATCAC -3′ GAPDH reverse: 5′-TCCACCACCCTGTTGCTGTA -3′
Equal volumes of PCR samples were subjected to electrophoresis in a 1% agarose gel, which was then stained with 0.1% ethidium bromide and photographed under ultraviolet illumination.
Quantitative real-time PCR
Superscript III platinum one-step qRT-PCR system (Invitrogen Co. Ltd, USA) was used for detection of VEGF, TGF-ß, CTGF, collagen-1 expression levels in LV. The 7500 real-time PCR system was used (Applied Biosystems Co. Ltd, USA). The sequences of the oligonucleotides were as follows: 15 VEGF forward: 5′-GAGGATGTCCTCACTCGGATG-3′ VEGF reverse: 5′-GTCGTGTTTCTGGAAGTGAGCAA-3′ TGF-ß forward: 5′-CAACAATTCCTGGCGTTACCTTGG-3′ TGF-ß reverse: 5′-GAAAGCCCTGTATTCCGTCTCCTT-3′ CTGF forward: 5′-CTCCACCCGAGTTACCAATGACAA-3′ CTGF reverse: 5′-CCAGAAAGCTCAAACTTGACAGGC-3′ Collagen-1 forward: 5′-GAGCGGAGAGTACTGGATCG-3′ Collagen-1 reverse: 5′-TACTCGAACGGGAATCCATC-3′ GAPDH forward: 5′-TGCTGAGTATGTCGTGGAGTCTA-3′ GAPDH reverse: 5′-AGTGGGAGTTGCTGTTGAAATC-3′
Morphometric analysis
After being fixed in 4% neutral formalin for 24 h, the LV was embedded in paraffin and cut into 4-µm thick sections, and then was stained with Masson's Trichrome staining.
Echocardiography
Mice were anesthetized with pentobarbital sodium (40 mg/ kg i.p.) and LV fractional shortening (FS) was measured using a high-resolution Doppler-echocardiographic system with a 12-MHz linear transducer (Acuson Aspen, USA).
Statistical analysis
All analyses were carried out with Stata 7.0 software system. Results are presented as mean ± standard deviation (SD). Differences in the data among the groups were compared by one-way ANOVA. Statistical significance was inferred at p < 0.05.
Results
Comparison of FBG
Comparison of FBG is shown in Table 1 . After STZ injection, FBG in DM group mice significantly increased, which indicated that a diabetic model was made. FBG in DM mice and DM-B mice were similar and both were much higher than control mice, which indicated that bosentan cannot decrease blood glucose.
Semiquantitative RT-PCR
Compared with mice in the control group, VEGF mRNA was down-regulated in DM group mice, and TGF-ß, CTGF, collagen-1 mRNA was up-regulated. The above mentioned changes in the DM group were nearly normalized in DM-B group. The RT-PCR result is shown in Figure 1 .
Quantitative real-time PCR
The real-time PCR result is shown in Figure 2 .
VEGF was decreased in both DM and DM-B mice compared with control mice (Figure 2A) . TGF-ß, CTGF, collagen-1 mRNA expressions were increased in both DM and DM-B mice compared with control mice (Figure 2 , B, C, There were no statistical differences among groups before STZ injection. One week and two weeks after STZ injection, FBG of DM mice and DM-B mice was much higher than control mice (p < 0.001), which indicated that a diabetic model obtained after STZ injection. After 18 weeks of the diabetic situation, FBG of DM-B mice was significantly higher than that of control mice and was similar to that of DM mice, which indicated that bosentan cannot ameliorate blood glucose.
and D). The changes of the above mentioned factors were ameliorated in DM-B mice compared with DM mice. These results indicated that bosentan can ameliorate the expressions of VEGF and fibrotic factors in LV in the diabetic situation.
Pathological changes after 18 weeks of diabetes
The result of Masson's Trichrome staining is shown in Figure 3 . Blue areas in the slice indicated fibrotic changes of myocardium. After 18 weeks of diabetes, DM mice showed significant myocardial fibrosis. The fibrotic changes can be ameliorated by bosentan in DM-B mice.
Cardiac function assessed by echocardiography
Representative M-mode echocardiography of control, DM-B, and DM mice are shown in Figure 4 . LVFS was significantly lowered in diabetic mice compared with controls. Treatment of diabetic mice with bosentan significantly ameliorated the cardiac function parameter.
Discussion
The present study addresses the hypothesis that the endothelin receptor antagonist, bosentan, can ameliorate diabetic cardiovascular complications. There has been increasing research interest in understanding the impact of the ET system on diabetic cardiovascular complications. Studies Compared with mice in the control group, VEGF mRNA was down-regulated in DM group mice, and TGF-ß, CTGF, collagen-1 mRNA was up-regulated. All the above mentioned factors in the DM-B group were similar to the control group, which indicated that bosentan normalized VEGF, TGF-ß, CTGF, and collagen-1 mRNA expression in LV when mice were under a diabetic situation.
found that the diabetic complications are partly consequences of an activated ET system, which could lead to myocardial and vascular dysfunction. 16 Unfortunately, few study attempts to clarify the potent protective effect of bosentan, a non-selective ETa and ETb receptor antagonist, 17 on diabetic cardiovascular complications, especially myocardial fibrosis. There has been increasing research interest in understanding the impact of diabetes on cardiovascular disease, 18, 19 and myocardial fibrosis is identified as an incurable complication. 20 The majority of previous studies revealed that high glucose is a potent activator for TGF-ß, CTGF and collagens, which promote AGEs production. 21 AGEs could directly stimulate the production of ECM, 9 which finally formats tissue fibrosis. Both type I and type III collagen are present in normal and diseased myocardial tissue. Type I collagen is predominant in the myocardium. 21, 22 Collagen-1 plays an important role in the formation of fibrosis. That is the reason why we evaluate the expression of those mediators. Also, VEGF is known to play an essential role in angiogenesis, and to participate in promoting the formation of new capillaries from pre-existing coronary vessels under some pathological conditions. Previous studies found a significant down expression of VEGF and its receptors in LV tissues of a streptozotocininduced diabetic animal model. 1 Previous work from another laboratory has also shown that, with the use of RT-PCR or Northern blot, cardiac gene expression of VEGF and its receptors is significantly decreased in STZ-induced diabetic rats as well as established diabetic patients with hypertension and/or myocardial infarction. 22 The present study demonstrated that cardiac expression of VEGF was down-regulated and fibrotic genes (TGF-ß, CTGF, collagen-1) were up-regulated in mice under a diabetic situation. VEGF, an endothelial cell-specific mitogen that is important in neovascularization under both physiological and pathophysiological conditions, plays a crucial role in developmental capillary formation and regulation of tissue angiogenesis. 1 A previous study showed that the myocardial expression level of VEGF mRNA was significantly decreased in STZ-induced diabetic animal models, and a two-fold reduction in VEGF was observed in autoptic ventricular specimens from diabetic patients compared with non-diabetic subjects. 23 TGF-ß and CTGF are involved in ECM accumulation both in the early and the later stages of diabetes. 24 Several lines of experimental and clinical evidence support a major role for TGF-ß in the development of interstitial fibrosis in diabetes. 25, 26 Inhibition of TGF-ß with neutralizing antibodies attenuated the excess matrix expression by reducing collagen and fibronectin mRNA. 25 CTGF is another prominent growth factor in the pathogenesis of diabetic cardiomyopathy. In experimental type 1 and type 2 diabetic models, CTGF mRNA and protein was upregulated in heart. 27 Increased myocardial CTGF mRNA was correlated with myocardial fibrosis. 28 Type I collagen is involved in myocardial ECM production. 8, 9 The present study demonstrated that endothelin blockade with bosentan reduced the expression of TGF-ß , CTGF, and collagen-1 and preserved the expression of VEGF, and thus ameliorated cardiac fibrosis.
Pathological analysis (paraffin embedding with Masson's Trichrome staining) in this study showed obvious cardiac fibrosis in diabetic mice. The above mentioned ultrastructural changes were significantly ameliorated by bosentan treatment.
Left ventricle enlargement was obviously recognized in the diabetic group, as evidenced by greater deterioration in LV fractional shortening. This is consistent with data reported in both clinical trials and animal studies examining the disease progression of heart failure in diabetic patients and animals. 1, 29, 30 The cardiac function was partially preserved in bosentan-treated mice.
Evidence is now strong for a role of the endothelin system in diabetes. Plasma ET-1 levels have been shown to be elevated in animal models of diabetes mellitus 31 and in diabetic patients. 32 Furthermore, it has been reported that ET-receptor antagonist reduced the production of ECM proteins in experimental diabetes. 16, 33 Thus the ET system appears to play a key role in the development of cardiovascular complications associated with diabetes and, therefore, therapy with intervention designed to suppress the ET system may prevent the development of cardiovascular complications in diabetes. The present study provides a comprehensive investigation of the VEGF, fibrotic genes (TGF-ß, CTGF, collagen-1), cardiac pathology and function changes under diabetic condition. The key data from this study provide substantial evidence that bosentan ameliorates cardiac dysfunction, LV fibrosis, and myocardial ultrastructure. The possible reason may be the retention of VEGF expression and diminishing of fibrotic genes. The exact mechanisms triggering the alteration in cardiac fibrosis in diabetes remain uncertain. However, the activation of the endothelin system may be involved in it, and endothelin inhibition may be suggested as one of the potential mechanisms to ameliorate cardiac fibrosis and to preserve cardiac function under the diabetic situation.
We believe the research direction is promising, but the question of whether or not these experimental results are also relevant in humans in the clinical setting and have therapeutic implications needs to be investigated further. 
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